Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The HDAC2/KAT2A-Lamin A Lactylation Axis Regulates Tumor Progression and Chemoresistance in Bladder Cancer.

Created on 15 Nov 2026

Authors

Guanghui Xu, Wei Zhao, Yuqin Li, Shuting Fang, Zhigang Wu, Minghao Zheng, Yongming Deng, Xi Zheng, Hongqian Guo, Wenli Diao, Junlong Zhuang

Published in

Cancer letters. Pages 218968. Nov 14, 2026. Epub Nov 14, 2026.

Abstract

Lysine lactylation (Kla) is a post-translational modification implicated in tumor metabolic reprogramming, yet its functional significance in bladder cancer remains largely unexplored. Here, we identify lactylation of Lamin A in bladder cancer and elucidate its regulatory mechanisms in cisplatin resistance. Integrated lactylome and proteome profiling combined with mass spectrometry reveal that Lamin A is lactylated at K233 and K417, which are significantly elevated in bladder cancer tissues. Functional characterization demonstrates that lactylation of Lamin A suppresses tumor proliferation, inhibits migration, induces G1 cell cycle arrest, promotes apoptosis, and thus enhances cisplatin sensitivity, whereas lactylation-deficient mutants abrogate these effects, with K233 and K417 as the critical functional residues. Mechanistically, Lamin A delactylation enhances the binding between MRE11 and ATM, promotes the recruitment of MRE11 to DSB sites and activates the downstream CHK1/CHK2 signaling pathway, thereby promoting DNA repair and conferring cisplatin resistance. We further identify HDAC2 and KAT2A as the delactylase and lactyltransferase of Lamin A, respectively, with HDAC2 driving malignant phenotypes through K233 and K417 delactylation. Pharmacological inhibition of HDAC2 with entinostat effectively suppresses xenograft tumor growth in vivo in a Lamin A lactylation-dependent manner. Collectively, our findings define Lamin A lactylation as a tumor-suppressive modification and uncover the HDAC2/KAT2A-Lamin A axis as a critical factor of cisplatin response, suggesting that targeting this pathway may represent a promising therapeutic strategy for bladder cancer.

PMID:
43034010
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement